greeksoup/ stock research
Stock research / United States / Funds / Deerfield Management Company, L.P.

Deerfield Management Company, L.P.

CIK 1009258 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Deerfield Management Company, L.P. reported 72 US-listed holdings worth $8.03 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Nuvalent Inc. (26.5%), Revolution Medicines, Inc. (5.6%) and Praxis Precision Medicines I (4.0%). Against the quarter before, it opened 11 positions, added to 13, trimmed 11 and sold out of 12.

Filed before as Deerfield Management Company, L.P. (series C).

Reported holdings$8.03B+11.9% on Q1 2026
Positions72-1 on Q1 2026
The largest ten57.1%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
Added toHeldTrimmed
NUVL26.5%RVMD5.6%PRAX4.0%VTRS4.0%CNC3.9%UTHR3.1%LEGN2.9%COGT2.4%GMAB2.3%BKD2.3%VERA2.1%IONS2.0%CELC1.9%58 more35.1%

The 14 largest of its 72 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $6.04 billion in 437 positions$6.04BQ3 24Q4 2024: $4.66 billion in 99 positions$4.66BQ4 24Q1 2025: $4.42 billion in 115 positions$4.42BQ1 25Q2 2025: $4.93 billion in 116 positions$4.93BQ2 25Q3 2025: $6.03 billion in 144 positions$6.03BQ3 25Q4 2025: $6.84 billion in 141 positions$6.84BQ4 25Q1 2026: $7.18 billion in 73 positions$7.18BQ1 26Q2 2026: $8.03 billion in 72 positions$8.03BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 11Added 13Held 37Trimmed 11Sold out 12
Opened: 11Added: 13Held: 37Trimmed: 11Sold out: 12

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 11

  1. Mineralys Therapeutics Inc. MLYS$106.8 million
  2. Boston Scientific Corp. BSX$56.1 million
  3. Parabilis Medicines Inc. Com PBLS$51.5 million
  4. Avalyn Pharma Inc. AVLN$24.1 million
  5. Odyssey Therapeutics, Inc. ODTX$19.6 million
  6. Alamar Biosciences Inc. ALMR$16.3 million
  7. Chemed Corp. CHE$14.0 million
  8. Adagene Inc. ADAG$11.2 million

and 3 more in the table below

Added to 13

  1. Genmab A/S GMAB+4.4 million shares · +179%
  2. Ideaya Biosciences Inc. IDYA+1.2 million shares · +77%
  3. Biomarin Pharmaceutical Inc. BMRN+481,280 shares · +57%
  4. Revolution Medicines, Inc. RVMD+95,000 shares · +4%
  5. Structure Therapeutics Inc. GPCR+318,007 shares · +41%
  6. Tyra Biosciences Inc. TYRA+468,000 shares · +85%
  7. Legend Biotech Corp. LEGN+450,000 shares · +6%
  8. Dianthus Therapeutics Inc. DNTH+105,500 shares · +10%

and 5 more in the table below

Trimmed 11

  1. Cogent Biosciences Inc. COGT-4.0 million shares · -45%
  2. Centene Corp. CNC-1.0 million shares · -17%
  3. Inspire Medical Systems, Inc. INSP-1.4 million shares · -52%
  4. Indivior Pharmaceuticals, Inc. INDV-1.4 million shares · -47%
  5. Veracyte, Inc. VCYT-625,000 shares · -86%
  6. Celcuity Inc. CELC-262,986 shares · -15%
  7. Arrowhead Pharmaceuticals, Inc. ARWR-184,242 shares · -12%
  8. Sionna Therapeutics Inc SION-289,674 shares · -30%

and 3 more in the table below

Sold out of 12

  1. Catalyst Pharmaceuticals Inc. CPRX$97.6 million last quarter
  2. Neurocrine Biosciences Inc. NBIX$80.4 million last quarter
  3. Day One Biopharmaceuticals I DAWN$79.8 million last quarter
  4. Enhabit Inc. EHAB$66.9 million last quarter
  5. Kymera Therapeutics Inc. KYMR$46.7 million last quarter
  6. Compass Therapeutics Inc. CMPX$19.1 million last quarter
  7. Taysha Gene Therapies Inc. TSHA$12.2 million last quarter
  8. Cullinan Therapeutics Inc. CGEM$5.5 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Nuvalent Inc. NUVL17,248,450$2.13 billion26.52%no change
Revolution Medicines, Inc. RVMD2,392,000$448.0 million5.58%+95,000
Praxis Precision Medicines I PRAX963,351$322.5 million4.02%no change
Viatris Inc. VTRS20,206,170$320.9 million4.00%no change
Centene Corp. CNC4,901,000$314.6 million3.92%-1,016,091
United Therapeutics Corp. UTHR457,000$247.6 million3.08%no change
Legend Biotech Corp. LEGN8,137,638$235.0 million2.93%+450,000
Cogent Biosciences Inc. COGT5,006,104$193.7 million2.41%-4,037,799
Genmab A/S GMAB6,865,000$188.6 million2.35%+4,403,000
Brookdale SR Living Inc. BKD11,637,032$187.2 million2.33%no change
Vera Therapeutics Inc. VERA3,916,400$168.1 million2.09%+194,300
Ionis Pharmaceuticals Inc. IONS1,979,669$157.0 million1.95%no change
Celcuity Inc. CELC1,451,014$151.8 million1.89%-262,986
Biocryst Pharmaceuticals Inc. BCRX15,096,403$151.0 million1.88%+58,403
Newamsterdam Pharma Company NAMS4,264,789$144.5 million1.80%no change
Acadia Healthcare Company, Inc. ACHC4,520,000$133.5 million1.66%no change
Tango Therapeutics Inc. TNGX4,190,611$131.0 million1.63%+43,798
AdaptHealth Corp. AHCO11,477,730$119.6 million1.49%no change
Pharvaris N V PHVS3,376,042$116.7 million1.45%+250,000
Arrowhead Pharmaceuticals, Inc. ARWR1,389,055$113.2 million1.41%-184,242
Dianthus Therapeutics Inc. DNTH1,125,313$109.7 million1.37%+105,500
Larimar Therapeutics Inc. LRMR35,606,974$108.6 million1.35%no change
Mineralys Therapeutics Inc. MLYS3,958,000$106.8 million1.33%new
Ideaya Biosciences Inc. IDYA2,714,503$101.2 million1.26%+1,184,495
Xenon Pharmaceuticals Inc. XENE1,615,696$97.5 million1.21%no change
Savara Inc. SVRA13,569,000$83.6 million1.04%no change
Lantheus Holdings, Inc. LNTH752,999$83.5 million1.04%-75,000
Syndax Pharmaceuticals Inc. SNDX3,779,900$82.6 million1.03%no change
Biomarin Pharmaceutical Inc. BMRN1,332,836$76.3 million0.95%+481,280
Pfizer Inc. PFE3,040,000$73.2 million0.91%no change
Indivior Pharmaceuticals, Inc. INDV1,648,895$67.7 million0.84%-1,448,895
Bio-Rad Laboratories, Inc. BIO226,070$66.4 million0.83%no change
Ars Pharmaceuticals Inc. SPRY7,503,812$60.1 million0.75%no change
Stoke Therapeutics Inc. STOK1,823,500$59.7 million0.74%no change
Structure Therapeutics Inc. GPCR1,086,000$58.3 million0.73%+318,007
Envista Holdings Corp. NVST2,210,100$58.2 million0.73%no change
Inspire Medical Systems, Inc. INSP1,296,862$57.9 million0.72%-1,406,376
Caredx Inc. CDNA1,997,618$56.9 million0.71%-193,382
Boston Scientific Corp. BSX1,315,000$56.1 million0.70%new
Belite Bio Inc. BLTE357,199$55.0 million0.68%+53,186
Parabilis Medicines Inc. Com PBLS1,880,704$51.5 million0.64%new
Certara, Inc. CERT7,512,928$49.2 million0.61%-295,677
Disc Medicine Inc. IRON657,000$48.1 million0.60%no change
Bridgebio Oncology Therapeutics Ord BBOT4,885,446$37.2 million0.46%no change
Tyra Biosciences Inc. TYRA1,017,000$32.5 million0.40%+468,000
Monopar Therapeutics Inc. MNPR323,745$30.0 million0.37%no change
Sionna Therapeutics Inc SION680,916$30.0 million0.37%-289,674
Avalyn Pharma Inc. AVLN731,000$24.1 million0.30%new
Foghorn Therapeutics Inc. FHTX4,394,367$21.4 million0.27%no change
Beta Bionics Inc BBNX1,324,000$20.7 million0.26%no change
Alnylam Pharmaceuticals Inc ALNY67,935$20.5 million0.25%no change
Bright Minds Biosciences Inc. DRUG283,000$19.9 million0.25%no change
Odyssey Therapeutics, Inc. ODTX1,046,139$19.6 million0.24%new
the Oncology Institute Inc. STLN3,360,052$18.2 million0.23%no change
Kyverna Therapeutics Inc. KYTX2,000,000$17.8 million0.22%no change
Alamar Biosciences Inc. ALMR600,000$16.3 million0.20%new
Chemed Corp. CHE30,000$14.0 million0.17%new
Spyglass Pharma Inc. SGP550,000$12.2 million0.15%no change
Adagene Inc. ADAG2,666,666$11.2 million0.14%new
Hemab Therapeutics Hldgs Inc. COAG275,000$10.1 million0.13%new
Mobia Med Inc. MOBI670,752$9.0 million0.11%new
Embecta Corp EMBC2,534,961$8.3 million0.10%no change
Veracyte, Inc. VCYT101,000$5.9 million0.07%-625,000
Annexon Inc. ANNX583,913$3.3 million0.04%no change
Alector Inc. ALEC1,055,192$2.1 million0.03%no change
Newamsterdam Pharma Company92,787$2.0 million0.02%no change
Edwards Lifesciences Corp. EW13,702$1.2 million0.02%no change
Mirum Pharmaceuticals Inc. MIRM6,027$705,5810.01%new
Humana Inc. HUM917$364,2510.00%no change
the Oncology Institute Inc. STLNW1,250,000$51,0000.00%no change
PMV Pharmaceuticals Inc. PMVP8,790$11,7790.00%no change
Surrozen Inc SRZNW166,666$2,7500.00%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 12 it sold out of are in the box above.